Lipitension today — disaster tomorrow: focus on elderly comorbid patients
https://doi.org/10.15829/1560-4071-2025-6340
EDN: HQWBFJ
Abstract
In elderly and senile patients, a combination of hypertension and atherogenic dyslipidemia is often encountered, which, both separately and in combination ("lipitension"), are associated with a high risk of cardiovascular events. In clinical practice, it is not just the age itself that is important, but the presence of geriatric syndromes in patients. In particular, frailty is characterized by a high risk of adverse outcomes and death, as well as loss of autonomy. This article presents current data on the efficacy and safety of antihypertensive and lipidlowering therapy in elderly patients. It also discusses the thesis that fixed-dose combination of amlodipine, perindopril and atorvastatin can increase adherence to therapy and ensure a balance between the efficacy and safety of treatment in elderly comorbid patients with a number of geriatric syndromes. The treatment of such patients is traditionally associated with polypharmacy and uncontrolled use of medications.
About the Authors
A. S. Skotnikov
Sechenov First Moscow State Medical University;
Russian State Social University
Russian Federation
Russian Federation
Moscow
V. D. Zakiev
Pirogov Russian National Research Medical University, Russian Gerontology Research and Clinical Center
Russian Federation
Russian Federation
Moscow
A. D. Gvozdeva
Botkin Multidisciplinary Research and Clinical Center
Russian Federation
Russian Federation
Moscow
L. G. Bektemirova
Main Clinical Hospital of the Ministry of Internal Affairs
Russian Federation
Russian Federation
Moscow
References
1. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA. 2002;287(8): 1003-10. doi:10.1001/jama.287.8.1003.
2. Fuchs FD, Whelton PK. High Blood Pressure and Cardiovascular Disease. Hypertension. 2020;75(2):285-92. doi:10.1161/HYPERTENSIONAHA.119.14240.
3. Dalal JJ, Padmanabhan TN, Jain P, et al. Lipitension: Interplay between dyslipidemia and hypertension. Indian J Endocrinol Metab. 2012;16(2):240-5. doi:10.4103/22308210.93742.
4. Wong ND, Lopez V, Tang S, Williams GR. Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States. Am J Cardiol. 2006; 98(2):204-8. doi:10.1016/j.amjcard.2006.01.079.
5. Wong ND, Lopez VA, Roberts CS, et al. Combined association of lipids and blood pressure in relation to incident cardiovascular disease in the elderly: the cardiovascular health study. Am J Hypertens. 2010;23(2):161-7. doi:10.1038/ajh.2009.216.
6. Bernard I.Symposium on hypertension in the elderly: should we treat hypertension in the elderly? Age and Ageing. 1979;8(2):115-20. doi:10.1093/ageing/8.2.115.
7. Amery A, Birkenhäger W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet. 1985;1(8442):1349-54.
8. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J (Clin Res Ed). 1986;293(6555):1145-51. doi:10.1136/bmj.293.6555.1145.
9. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991;265(24):3255-64.
10. Dahlöf B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 1991;338(8778):1281-5. doi:10.1016/0140-6736(91)92589-t.
11. Gong L, Zhang W, Zhu Y, et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens. 1996;14(10):1237-45. doi:10.1097/00004872-199610000-00013.
12. Tkacheva ON, Kotovskaya YuV, Runikhina NK, et al. Clinical Guidelines on Frailty. Russian Journal of Geriatric Medicine. 2025;(1):6-48. (In Russ.) doi:10.37586/2686-8636-1-2025-6-48.
13. Ji L, Jazwinski SM, Kim S.Frailty and Biological Age. Ann Geriatr Med Res. 2021;25(3): 141-9. doi:10.4235/agmr.21.0080.
14. Bai G, Wang Y, Mak JKL, et al. Is Frailty Different in Younger Adults Compared to Old? Prevalence, Characteristics, and Risk Factors of Early-Life and Late-Life Frailty in Samples from Sweden and UK. Gerontology. 2023;69(12):1385-93. doi:10.1159/000534131.
15. Vetrano DL, Palmer KM, Galluzzo L, et al. Hypertension and frailty: a systematic review and meta-analysis. BMJ Open. 2018;8(12):e024406. doi:10.1136/bmjopen-2018-024406.
16. Cherubini A, Del Signore S, Ouslander J, et al. Fighting against age discrimination in clinical trials. J Am Geriatr Soc. 2010;58(9):1791-6. doi:10.1111/j.1532-5415.2010.03032.x.
17. Wright JT Jr, Williamson JD, Whelton PK, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373(22):2103-16. doi:10.1056/NEJMoa1511939.
18. Williamson JD, Supiano MA, Applegate WB, et al. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial. JAMA. 2016;315(24):2673-82. doi:10.1001/jama.2016.7050.
19. Liu J, Li Y, Ge J, et al. Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial. Lancet. 2024;404(10449):245-55. doi:10.1016/S0140-6736(24)01028-6.
20. Zhang W, Zhang S, Deng Y, et al. Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension. N Engl J Med. 2021;385(14):1268-79. doi:10.1056/NEJMoa2111437.
21. Blood Pressure Lowering Treatment Trialists' Collaboration. Age-stratified and bloodpressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data metaanalysis. Lancet. 2021;398(10305):1053-64. doi:10.1016/S0140-6736(21)01921-8.
22. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887-98. doi:10.1056/NEJMoa0801369.
23. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159-219. doi:10.1093/eurheartj/eht151.
24. Nguyen TN, Harris K, Woodward M, et al. The Impact of Frailty on the Effectiveness and Safety of Intensive Glucose Control and Blood Pressure-Lowering Therapy for People With Type 2 Diabetes: Results From the ADVANCE Trial. Diabetes Care. 2021;44(7):1622-19. doi:10.2337/dc20-2664.
25. Warwick J, Falaschetti E, Rockwood K, et al. No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the HYpertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over. BMC Med. 2015;13:78. doi:10.1186/s12916-015-0328-1.
26. Searle SD, Mitnitski A, Gahbauer EA, et al. A standard procedure for creating a frailty index. BMC Geriatr. 2008;8:24. doi:10.1186/1471-2318-8-24.
27. McEvoy JW, McCarthy CP, Bruno RM, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912-4018. doi:10.1093/eurheartj/ehae178. Erratum in: Eur Heart J. 2025:ehaf031. doi:10.1093/eurheartj/ehaf031.
28. O'Donoghue P, O'Halloran AM, Kenny RA, Romero-Ortuno R. Do the frail experience more adverse events from intensive blood pressure control? A 2-year prospective study in the Irish Longitudinal Study on Ageing (TILDA). EClinicalMedicine. 2022;45:101304. doi:10.1016/j.eclinm.2022.
29. Todd OM, Wilkinson C, Hale M, et al. Is the association between blood pressure and mortality in older adults different with frailty? A systematic review and meta-analysis. Age Ageing. 2019;48(5):627-35. doi:10.1093/ageing/afz072.
30. Benetos A, Petrovic M, Strandberg T. Hypertension Management in Older and Frail Older Patients. Circ Res. 2019;124(7):1045-60. doi:10.1161/CIRCRESAHA.118.313236.
31. Bencivenga L, De Souto Barreto P, Rolland Y, et al. Blood pressure variability: A potential marker of aging. Ageing Res Rev. 2022;80:101677. doi:10.1016/j.arr.2022.101677.
32. Chowdhury EK, Nelson MR, Wing LMH, et al. Second Australian National Blood Pressure Study Change in Blood Pressure Variability Among Treated Elderly Hypertensive Patients and Its Association With Mortality. J Am Heart Assoc. 2019;8(21):e012630. doi:10.1161/JAHA.119.012630.
33. Nardin C, Rattazzi M, Pauletto P. Blood Pressure Variability and Therapeutic Implications in Hypertension and Cardiovascular Diseases. High Blood Press Cardiovasc Prev. 2019; 26(5):353-9. doi:10.1007/s40292-019-00339-z.
34. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895-906. doi:10.1016/S0140-6736(05)67185-1.
35. Rothwell PM, Howard SC, Dolan E, et al. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol. 2010;9(5):469-80. doi:10.1016/S1474-4422(10)70066-1.
36. Gupta A, Whiteley WN, Godec T, et al. Legacy benefits of blood pressure treatment on cardiovascular events are primarily mediated by improved blood pressure variability: the ASCOT trial. Eur Heart J. 2024;45(13):1159-69. doi:10.1093/eurheartj/ehad814.
37. Chang TI, Reboussin DM, Chertow GM, et al. Visit-to-Visit Office Blood Pressure Variability and Cardiovascular Outcomes in SPRINT (Systolic Blood Pressure Intervention Trial). Hypertension. 2017;70(4):751-8. doi:10.1161/HYPERTENSIONAHA.117.09788.
38. Glezer MG. Antihypertensive Effect of Switching to a Fixed Perindopril/Amlodipine Combination in Patients Ineffectively Treated by Free Sartan-Containing Combinations. Results of the AVANGARD Study. Kardiologiia. 2019;59(10):31-8. (In Russ.) doi:10.18087/cardio.2019.10.n731.
39. Ezhov MV, Kukharchuk VV, Sergienko IV, et al. Disorders of lipid metabolism. Clinical Guidelines 2023. Russian Journal of Cardiology. 2023;28(5):5471. (In Russ.) doi:10.15829/1560-4071-2023-5471.
40. Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019;393(10170):407-15. doi:10.1016/S0140-6736(18)31942-1.
41. Bao A, Karalis DG. Statin Therapy for Primary and Secondary Prevention in Older Adults. Curr Atheroscler Rep. 2024;27(1):11. doi:10.1007/s11883-024-01257-9.
42. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364): 1149-58. doi:10.1016/S0140-6736(03)12948-0.
43. Collier DJ, Poulter NR, Dahlöf B, et al. Impact of atorvastatin among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm. J Hypertens. 2011;29(3):592-9. doi:10.1097/HJH.0b013e328342c8f7.
44. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685-96. doi:10.1016/S0140-6736(04)16895-5.
45. Neil HA, DeMicco DA, Luo D, et al. Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care. 2006;29(11):2378-84. doi:10.2337/dc06-0872.
46. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346): 1623-30. doi:10.1016/s0140-6736(02)11600-x.
47. Zhou Z, Ofori-Asenso R, Curtis AJ, et al. Association of Statin Use With Disability-Free Survival and Cardiovascular Disease Among Healthy Older Adults. J Am Coll Cardiol. 2020;76(1):17-27. doi:10.1016/j.jacc.2020.05.016.
48. Schech S, Graham D, Staffa J, et al. Risk factors for statin-associated rhabdomyolysis. Pharmacoepidemiol Drug Saf. 2007;16(3):352-8. doi:10.1002/pds.1287.
49. Zhou Z, Albarqouni L, Curtis AJ, et al. The Safety and Tolerability of Statin Therapy in Primary Prevention in Older Adults: A Systematic Review and Meta-analysis. Drugs Aging. 2020;37(3):175-85. doi:10.1007/s40266-019-00736-y.
50. Iwere RB, Hewitt J. Myopathy in older people receiving statin therapy: a systematic review and meta-analysis. Br J Clin Pharmacol. 2015;80(3):363-71. doi:10.1111/bcp.12687.
51. Nanna MG, Navar AM, Wang TY, et al. Statin Use and Adverse Effects Among Adults >75 Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry. J Am Heart Assoc. 2018;7(10):e008546. doi:10.1161/JAHA. 118.008546.
52. Kotovskaya YV, Tkacheva ON, Sergienko IV. Lipid-Lowering Therapy for Primary Cardiovascular Prevention in Older Adults. Consensus Statement of the Russian Association of Gerontologists and Geriatricians, National Society on Atherosclerosis, Russian Society of Cardiology, Association of Clinical Pharmacologists. Kardiologiia. 2020;60(6):119-32. (In Russ.) doi:10.18087/cardio.2020.6.n1037.
53. Horodinschi RN, Stanescu AMA, Bratu OG, et al. Treatment with Statins in Elderly Patients. Medicina (Kaunas). 2019;55(11):721. doi:10.3390/medicina55110721.
54. Zoungas S, Curtis A, Spark S, et al. Statins for extension of disability-free survival and primary prevention of cardiovascular events among older people: protocol for a randomised controlled trial in primary care (STAREE trial). BMJ Open. 2023;13(4):e069915. doi:10.1136/bmjopen-2022-069915.
55. Joseph J, Pajewski NM, Dolor RJ, et al. Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): Trial design and rationale. J Am Geriatr Soc. 2023;71(6):1701-13. doi:10.1111/jgs.18312.
Review
For citations:
Skotnikov A.S., Zakiev V.D., Gvozdeva A.D., Bektemirova L.G. Lipitension today — disaster tomorrow: focus on elderly comorbid patients. Russian Journal of Cardiology. 2025;30(4):6340. (In Russ.) https://doi.org/10.15829/1560-4071-2025-6340. EDN: HQWBFJ
Views:
265
Email this article 